Advanced HER2-Positive Breast Cancer: Update on Destiny-Breast03 Data

Mark Pegram, MD, and Sara Tolaney, MD, review data from DESTINY-Breast03 trial and implications of these data for treatment of patients with HER2+ breast cancer going forward.

EP. 1: Historical Perspective of HER2+ Breast Cancer

October 21st 2021

Mark Pegram, MD, provides a historical perspective on recent advancements made in the treatment landscape for patients with HER2-positive breast cancer.

EP. 2: Trastuzumab Derxutecan in HER2+ mBC

October 21st 2021

Sara Tolaney, MD, describes trastuzumab deruxtecan and the data that led to its accelerated approval in HER2+ breast cancer.

EP. 3: DESTINY-Breast03 Trial in HER2+ mBC

October 21st 2021

Mark Pegram, MD, and Sara Tolaney, MD, review the DESTINY-Breast03 study design, clinical efficacy, and safety data.

EP. 4: Experience with Trastuzumab Deruxtecan in Breast Cancer

October 21st 2021

Breast cancer experts, Sara Tolaney, MD, and Mark Pegram, MD, discuss current standard of care in sequencing of therapies in mBC and the effect of DESTINY-Breast03 data on sequencing going forward.

EP. 5: Sequencing in HER2+ MBC

October 26th 2021

Sara Tolaney, MD, and Mark Pegram, MD, discuss their rationale for sequencing of most effective therapy in treatment of patients with metastatic breast cancer.

EP. 6: Other Trials with Trastuzumab Deruxtecan in Breast Cancer

October 26th 2021

Breast cancer experts, Drs. Sara Tolaney and Mark Pegram discuss ongoing and noteworthy trials with trastuzumab deruxtecan in mBC.

EP. 7: Future Landscape of HER2+ MBC

October 26th 2021

Drs. Sara Tolaney and Mark Pegram discuss promising therapies and upcoming mechanisms of actions to treat HER2+ metastatic breast cancer.